UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 28, 2016
AEGERION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-34921 |
|
20-2960116 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Identification No.) |
One Main Street, Suite 800
Cambridge, MA 02142
(Address of principal executive offices)
Registrants telephone number, including area code: (617) 500-7867
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
o Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
Aegerion Pharmaceuticals, Inc. (the Company) held its Annual Meeting of Stockholders (the Annual Meeting) on June 28, 2016. At the Annual Meeting, the Companys stockholders elected David I. Scheer, Donald K. Stern and Mary Szela as Class III directors, to serve on the Board of Directors of the Company until the Companys 2019 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. The voting results for this proposal were as follows:
|
|
For |
|
Withheld |
|
Broker Non- |
|
David I. Scheer |
|
17,226,069 |
|
2,649,678 |
|
5,182,332 |
|
Donald K. Stern |
|
19,785,270 |
|
90,477 |
|
5,182,332 |
|
Mary Szela |
|
19,472,794 |
|
402,953 |
|
5,182,332 |
|
The Companys stockholders also voted to ratify the selection of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016. The voting results for this proposal were as follows:
For |
|
Against |
|
Abstaining |
|
Broker Non-Votes |
|
24,968,196 |
|
84,010 |
|
5,873 |
|
0 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 5, 2016
|
AEGERION PHARMACEUTICALS, INC. | |
|
| |
|
|
|
|
By: |
/s/ /Gregory D. Perry |
|
|
Gregory D. Perry |
|
|
Chief Financial and Administrative Officer |